Hepatocyte growth factor (HGF) is a pleiotropic cytokine with cardioprotective properties. Serum HGF concentration is markedly raised in end stage renal disease (ESRD). The objective of this study was to assess the relationship of HGF with left ventricular (LV) mass and geometry in ESRD. Serum HGF measurements (ELISA) and echocardiographic studies were performed in 185 hemodyalisis patients. Patients with serum HGF above the median (1.85 ng/ml) had had more frequent cardiovascular complications. Serum HGF was directly related to mean LV wall thickness (r=0.23, P=0.002) and relative wall thickness (r=0.25, P=0.0001) and a multivariate analysis showed that this relationship was independent of other risk factors. Accordingly, the prevalence of LV concentric geometry (either concentric LVH or LV concentric remodelling) was much higher (n=49, 53%) among patients with HGF values above the median that in those with HGF less than or equal to 1.85 ng/ml (n=31, 34%). Furthermore, the risk for LV concentric geometry was higher in patients with HGF values above the median (odds ratio 2.57, 95% CI: 1.33-4.98, P=0.005) and multiple logistic regression analysis confirmed that this association was independent of other risk factors. In hemodialysis patients, elevated serum HGF is associated with concentric LV geometry. This is consistent with reports that link HGF to arterial remodelling and survival in ESRD patients, and suggests that this cytokine is part of a counter-regulatory response aimed at attenuating cardiovascular damage in this high risk population. Key words: HGF, cytokines, dialysis, cardiac remodelling, LVH, concentric LVH.
Hepatocyte growth factor and left ventricular geometry in end-stage renal disease.
Tripepi G;
2003
Abstract
Hepatocyte growth factor (HGF) is a pleiotropic cytokine with cardioprotective properties. Serum HGF concentration is markedly raised in end stage renal disease (ESRD). The objective of this study was to assess the relationship of HGF with left ventricular (LV) mass and geometry in ESRD. Serum HGF measurements (ELISA) and echocardiographic studies were performed in 185 hemodyalisis patients. Patients with serum HGF above the median (1.85 ng/ml) had had more frequent cardiovascular complications. Serum HGF was directly related to mean LV wall thickness (r=0.23, P=0.002) and relative wall thickness (r=0.25, P=0.0001) and a multivariate analysis showed that this relationship was independent of other risk factors. Accordingly, the prevalence of LV concentric geometry (either concentric LVH or LV concentric remodelling) was much higher (n=49, 53%) among patients with HGF values above the median that in those with HGF less than or equal to 1.85 ng/ml (n=31, 34%). Furthermore, the risk for LV concentric geometry was higher in patients with HGF values above the median (odds ratio 2.57, 95% CI: 1.33-4.98, P=0.005) and multiple logistic regression analysis confirmed that this association was independent of other risk factors. In hemodialysis patients, elevated serum HGF is associated with concentric LV geometry. This is consistent with reports that link HGF to arterial remodelling and survival in ESRD patients, and suggests that this cytokine is part of a counter-regulatory response aimed at attenuating cardiovascular damage in this high risk population. Key words: HGF, cytokines, dialysis, cardiac remodelling, LVH, concentric LVH.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
